Detalhe da pesquisa
1.
Measuring ovarian toxicity in clinical trials: an American Society of Clinical Oncology research statement.
Lancet Oncol
; 24(10): e415-e423, 2023 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-37797647
2.
The Development of the Oncology Center of Excellence Patient-Friendly Language Glossary of Oncology Clinical Trial Terms.
Oncologist
; 28(5): 379-382, 2023 05 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-36882084
3.
Overall survival in patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer treated with a cyclin-dependent kinase 4/6 inhibitor plus fulvestrant: a US Food and Drug Administration pooled analysis.
Lancet Oncol
; 22(11): 1573-1581, 2021 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-34656225
4.
Survival outcomes in older men with non-metastatic castration-resistant prostate cancer treated with androgen receptor inhibitors: a US Food and Drug Administration pooled analysis of patient-level data from three randomised trials.
Lancet Oncol
; 22(9): 1230-1239, 2021 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-34310904
5.
Systematic Review of PD-1/PD-L1 Inhibitors in Oncology: From Personalized Medicine to Public Health.
Oncologist
; 26(10): e1786-e1799, 2021 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-34196068
6.
FDA Approval Summary: Olaparib Monotherapy or in Combination with Bevacizumab for the Maintenance Treatment of Patients with Advanced Ovarian Cancer.
Oncologist
; 26(1): e164-e172, 2021 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33017510
7.
FDA Approval Summary: Rucaparib for the Treatment of Patients with Deleterious BRCA-Mutated Metastatic Castrate-Resistant Prostate Cancer.
Oncologist
; 26(2): 139-146, 2021 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-33145877
8.
US Food and Drug Administration regulatory updates in neuro-oncology.
J Neurooncol
; 153(3): 375-381, 2021 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-34156585
9.
Arterial aneurysm and dissection with systemic vascular endothelial growth factor inhibitors: A review of cases reported to the FDA Adverse Event Reporting System and published in the literature.
Vasc Med
; 26(5): 526-534, 2021 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-33840328
10.
CDK4/6 inhibitor treatment for patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer: a US Food and Drug Administration pooled analysis.
Lancet Oncol
; 21(2): 250-260, 2020 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-31859246
11.
Cardio-Oncology: Vascular and Metabolic Perspectives: A Scientific Statement From the American Heart Association.
Circulation
; 139(13): e579-e602, 2019 03 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-30786722
12.
Myocarditis in the Setting of Cancer Therapeutics: Proposed Case Definitions for Emerging Clinical Syndromes in Cardio-Oncology
Circulation
; 140(2): 80-91, 2019 07 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-31390169
13.
Fatal neutropenic enterocolitis associated with docetaxel use: A review of cases reported to the United States Food and Drug Administration Adverse Event Reporting System.
J Oncol Pharm Pract
; 26(4): 923-928, 2020 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-31594460
14.
Patient-Friendly Language to Facilitate Treatment Choice for Patients with Cancer.
Oncologist
; 24(8): 1011-1012, 2019 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-31097617
15.
Myocarditis Associated with Immune Checkpoint Inhibitors: An Expert Consensus on Data Gaps and a Call to Action.
Oncologist
; 23(8): 874-878, 2018 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-29802220
16.
The TRAIL receptor agonist drozitumab targets basal B triple-negative breast cancer cells that express vimentin and Axl.
Breast Cancer Res Treat
; 155(2): 235-51, 2016 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-26759246
17.
Corrigendum to "Assessing cardiac safety in oncology drug development" [Am Heart J 214 (2019) 125-133].
Am Heart J
; 218: 133, 2019 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-31806089
18.
Assessing cardiac safety in oncology drug development.
Am Heart J
; 214: 125-133, 2019 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-31202099
19.
Cytoreductive nephrectomy in the era of immune checkpoint inhibitors: a U.S. FDA pooled analysis.
J Natl Cancer Inst
; 2024 Mar 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-38486364
20.
FDA Approval Summary: Enfortumab Vedotin plus Pembrolizumab for Cisplatin-Ineligible Locally Advanced or Metastatic Urothelial Carcinoma.
Clin Cancer Res
; 30(10): 2011-2016, 2024 May 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-38441576